Kanorskiy S G, Borisenko Y V
Federal State Budgetary Educational Institution of Higher Education "Kuban State Medical University" of the Ministry of Health of the Russian Federation.
Kardiologiia. 2018 Jun;58(6):85-89.
Chronic heart failure with preserved ejection fraction (HFpEF) accounts for about 50% of cases of heart failure, but pharmacotherapy that improves its outcomes has not been developed. The proven principle of improving outcomes in patients with chronic heart failure with a reduced of left ventricular ejection fraction is the decrease in heart rate. The article discusses situations in which treatment with β-blockers is not effective or negatively affects outcomes. The results of own research and the EDIFY project, in which ivabradine was used in patients with HFpEF, were compared. The importance of phenotyping patients with HFpEF is stated to increase the effectiveness of their therapy.
射血分数保留的慢性心力衰竭（HFpEF）约占心力衰竭病例的50%，但尚未开发出能改善其预后的药物治疗方法。已证实的改善左心室射血分数降低的慢性心力衰竭患者预后的原则是降低心率。本文讨论了β受体阻滞剂治疗无效或对预后产生负面影响的情况。比较了自身研究结果和EDIFY项目（该项目在HFpEF患者中使用了伊伐布雷定）的结果。文中指出对HFpEF患者进行表型分析对于提高其治疗效果的重要性。
